NCT03993327View on ClinicalTrials.gov

An Imaging Agent (I-124 M5A) in Detecting CEA-Positive Liver Metastases in Patients With Colorectal Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

July 15, 2020

Primary Completion Date

June 4, 2024

Study Completion Date

June 4, 2024

Conditions
Colorectal Carcinoma Metastatic in the LiverMetastatic Colorectal CarcinomaStage IV Colorectal Cancer AJCC v8Stage IVA Colorectal Cancer AJCC v8Stage IVB Colorectal Cancer AJCC v8Stage IVC Colorectal Cancer AJCC v8
Interventions
BIOLOGICAL

Iodine I 124 Monoclonal Antibody M5A

Given IV

PROCEDURE

Positron Emission Tomography

Undergo PET scan

Trial Locations (1)

91010

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER

NCT03993327 - An Imaging Agent (I-124 M5A) in Detecting CEA-Positive Liver Metastases in Patients With Colorectal Cancer | Biotech Hunter | Biotech Hunter